David W. Gryska

Mr. Gryska joined their Board of Directors in January 2012. Since March 2005, he also served as a board member at Seattle Genetics. From December 2006 to October 2010, Mr. Gryska was Senior Vice President and Chief Financial Officer of Celgene. Previously, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. From 1998 to 2004, Mr. Gryska was Senior Vice President and Chief Financial Officer at Scios, Inc., a biopharmaceutical company, where he led the transaction effort for the successful sale of the company to Johnson & Johnson for $2.5 billion in February 2003. From 1993 to 1998, he served as Vice President and Chief Financial Officer at Cardiac Pathways, a company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Mr. Gryska also serves on the Board of Directors of Hyperion Therapeutics. He holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University.